Navigation Links
ADVENTRX Reports Second Quarter 2011 Financial Results
Date:8/8/2011

iming of initiating clinical studies of ANX-188 and ANX-514. Actual events or results may differ materially from those expressed or implied by the forward-looking statements in this press release due to a number of risks and uncertainties, including, without limitation: the risk that ADVENTRX does not receive FDA approval of Exelbine on a timely basis, or at all; the potential for the FDA to impose requirements to be completed before or after approval of the Exelbine NDA; difficulties or delays in marketing Exelbine, if approved, including developing or acquiring additional marketing, sales and distribution capabilities; difficulties or delays in manufacturing Exelbine at commercial scale, if approved, including validating commercial manufacturing processes and manufacturers, as well as other suppliers, and the risk of supply shortages; the risk that Exelbine, if approved, does not achieve broad market acceptance, including as a result of limited differentiation (or ability to promote differentiation) from Navelbine® and its generic equivalents; the risk that Exelbine cannot be priced at levels that exceed its fully-burdened manufacturing cost or that provide a reasonable return on investment to ADVENTRX; the risk that any patent issued to ADVENTRX may not provide sufficient protection and market exclusivity for Exelbine and may be challenged, invalidated, infringed or circumvented by third parties, including by ADVENTRX's competitors; ADVENTRX's dependence on the success of Exelbine as its first product candidate to be submitted for regulatory approval; difficulties or delays in reaching agreement with the FDA on the clinical development of ANX-188 and ANX-514; the potential for the FDA to require significant additional clinical and/or nonclinical studies of ADVENTRX's lead product candidates, in addition to its planned clinical trials of ANX-188 and ANX-514, and that ADVENTRX consequently determines to discontinue one or more of those development programs; di
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ADVENTRX Pharmaceuticals to Present at the 31st Annual Canaccord Genuity Growth Conference on August 11
2. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
3. ADVENTRX Reports First Quarter 2011 Financial Results
4. ADVENTRX Completes Acquisition of SynthRx
5. ADVENTRX Pharmaceuticals Provides Update on ANX-514
6. ADVENTRX Signs Definitive Agreement to Acquire SynthRx Inc.
7. ADVENTRX to Provide Update Regarding Pipeline Expansion Efforts
8. ADVENTRX Pharmaceuticals to Present at the 13th Annual BIOCEO & Investor Conference on February 15
9. ADVENTRX Pharmaceuticals Receives PDUFA Date for Exelbine™ NDA
10. ADVENTRX Pharmaceuticals Announces Closing of $22.5 Million Financing
11. ADVENTRX Pharmaceuticals Announces Capital Raise of $22.5 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014  Breg, Inc., a premier ... launched the FreeRunner™ knee brace with new innovations ... patella mal-tracking return to active lifestyles.  FreeRunner,s patent-pending ... braces, providing support when patients need it most, ... don,t. Patellofemoral issues are the most ...
(Date:7/10/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... the sale to Galderma of all rights to Restylane, ... Valeant for $1.4 billion in cash, pursuant to the ... its acquisition of Galderma. "We are ... a company that is firmly committed to the aesthetic ...
(Date:7/10/2014)... , July 10, 2014 Decision Resources ... awareness of the U.S. Food and Drug Administration,s (FDA) ... phosphate binder Velphoro, which was approved by the FDA ... chronic kidney disease (CKD) patients on dialysis. ... TreatmentTrends: Nephrology (US) Q2 2014 : ...
Breaking Medicine Technology:Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 2Half of Surveyed Nephrologists Report Moderate Familiarity with Velphoro, Which Received FDA Approval Late Last Year for the Treatment of Hyperphosphatemia in Dialysis 3
... LAGUNA HILLS, Calif., Oct. 6 Minnow Medical, Inc., ... thermoplasty for the treatment of in-stent restenosis and other ... veteran medical device executives. Prabodh Mathur ... K. Handley has been named vice president of quality, ...
... Oct. 6 Ferring Pharmaceuticals Inc. today announced ... trials of LYSTEDA™ (tranexamic acid) tablets for cyclic ... of the peer-reviewed journal, Obstetrics & Gynecology ... significantly reduced menstrual blood loss from baseline, and ...
Cached Medicine Technology:Minnow Medical Bolsters Management Team 2Minnow Medical Bolsters Management Team 3Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 2Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 3Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study 4
(Date:7/11/2014)... GA (PRWEB) July 11, 2014 Datalogic ... step in improving sanitation hospital wide. With their new ... the spread of disease, like the devastating MRSA, which ... The Gryphon GD4400-HC 2D and the Gryphon ... 2D barcodes and can even read barcodes off of ...
(Date:7/11/2014)... -- U.S. health officials have concluded that it,s highly ... during a safety mishap last month. But, the ... announced a moratorium on the transfer of any dangerous ... a report issued Friday, the CDC outlined several measures ... incident doesn,t occur again. Last month, as many as ...
(Date:7/11/2014)... enterprises today are shifting towards the changing trend in ... offer these global enterprises a strategic method to cut ... operational costs to companies. The aim to minimize operational ... market driver for expanding the managed services market in ... estimated to grow from $142.75 billion in 2013 to ...
(Date:7/11/2014)... 10, 2014) Obese and overweight firefighters are ... care providers, according to new research from The ... (UTHealth). , National guidelines state that health care ... of maintaining a healthy weight. Firefighters have high ... leading cause of line-of-duty deaths in firefighters. This ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- Prostate cancer patients are ... less effective treatment and die sooner if they also ... data from more than 41,200 American men who were ... They followed them through 2009. Nearly 1,900 of the ... years before their prostate cancer was discovered. "Men ...
Breaking Medicine News(10 mins):Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 2Health News:Stop Spreading Disease with the New Disinfectant-Ready Bar Code Scanner 3Health News:CDC Issues Tough Report on Anthrax Scare 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Depression May Make It Harder to Beat Prostate Cancer 2
... Germany and America who had treated injured protestors while ... to // leave Nepal by the King Gyanendra's government. ... detained Wednesday after he appeared on a private television ... brutally assaulted by the security forces. ,On ...
... at the McDonald’s or KFC restaurants, across the world, have ... levels of the same // food elsewhere. ,According to ... of Medicine, the researchers analysed various food items like McDonald's ... in many countries between 2004 and 2005, the Associated Press ...
... that been launched on a trial basis in Singapore would ... intensive care unit//. A camera hooked up beside the baby's ... to view the live footage on 3G-enabled mobile phones, Singapore ... on a three-month trial, during which the infants go online ...
... symposium titled ‘Challenging Intellectual Property’ will be analyzed and ... ,The Symposium will look into the aspects of ... production in economic development. It will also gauge the ... table, desirous of bringing a change in health research ...
... way to reverse the process of cell division. This ... could be an important milestone in the fight// against ... from the Oklahoma Medical Research Foundation have published their ... a million times in the human body each day. ...
... If you thought that McDonalds’ in USA serves the same ... and// think!,According to a study by three Danish doctors, fat ... as "trans fat" in foods purchased at McDonald's Corp and ... to the staggering research published in this week's New England ...
Cached Medicine News:
Helmer's Horizon Series line of refrigerators are designed specifically for the cost conscious buyer. This line offers outstanding performance, quality, and the features you need to ensure the safety...
... presents i.Series refrigerators ... solutions for the blood ... features than ever before, ... are at the forefront ...
This storage freezer, which is based on our premium freezer line, maintain red cells safely below regulatory standards at -86C (-123F). Recorder is standard for model 8627. Model 8627 is UL Listed, C...
The TBR-360-1-GD is a large capacity upright style operating temperature +4C. It is specially designed refrigerators for the storage of blood in standard 500ml bags, complying with Australian Standar...
Medicine Products: